Smith A, Waibel R, Stahel R A
Department of Medicine, University Hospital, Zürich, Switzerland.
Br J Cancer. 1991 Aug;64(2):263-6. doi: 10.1038/bjc.1991.289.
Intact SWA11 antibody was evaluated as a potential radioimmunotherapeutic agent against small cell lung cancer xenografts in a nude mouse model system. 131I-labelled SWA11 was given either in a single injection regimen (1 x 300 microCi) or as a multiple injection regimen achieving a total of 900 microCi (3 x 300 microCi with a 2 week interval between injections). Treatment of both small (mean volume approximately 0.2 cm3) and large (mean volume approximately 1.0 cm3) established xenografts resulted in significant anti-tumour effects and, in the case of the fractionated protocol, the failure of the xenografts to regrow within the period of observation (84 days). Xenograft histology following radioimmunotherapy showed large areas of necrosis, fibrosis and very few residual cells of SCLC origin.
在裸鼠模型系统中，对完整的SWA11抗体作为抗小细胞肺癌异种移植瘤的潜在放射免疫治疗剂进行了评估。131I标记的SWA11以单次注射方案（1×300微居里）给药，或以多次注射方案给药，总剂量达到900微居里（3×300微居里，注射间隔为2周）。对小型（平均体积约0.2立方厘米）和大型（平均体积约1.0立方厘米）已形成的异种移植瘤进行治疗均产生了显著的抗肿瘤效果，并且在分次给药方案中，异种移植瘤在观察期（84天）内未能重新生长。放射免疫治疗后的异种移植瘤组织学显示大面积坏死、纤维化，且很少有小细胞肺癌来源的残留细胞。
